Yale Researchers Use Zebrafish to Develop Precision Autism Treatments

Researchers at Yale have developed a method to identify potential precision treatments for autism spectrum disorder (ASD) by utilizing zebrafish and a comprehensive database of approved medications.

In a study published in the journal Proceedings of the National Academy of Sciences, the research team generated a database of 520 U.S. Food and Drug Administration (FDA)-approved drugs. They used this database to analyze the effects of these medications on the basic behaviors of larval zebrafish.

The team specifically sought to identify drug candidates that could reverse disrupted behaviors in zebrafish that carried mutations in autism risk genes. These candidates may represent potential targets for humans who carry mutations in those same specific risk genes.

The Need for Precision Medicine in Autism

The study emphasizes a shift toward precision medicine because autism spectrum disorder is characterized by significant clinical and genetic heterogeneity. This diversity makes it difficult to identify drug candidates that work for all patients, often leading to the failure of new drugs during clinical trials.

Ellen J. Hoffman, an associate professor at the Yale Child Study Center at Yale School of Medicine and the senior author of the study, explained the challenge of treating the disorder:

Because autism spectrum disorder is highly clinically and genetically heterogeneous, it is challenging to identify drug candidates and many new drugs under investigation are not effective in clinical trials,

Ellen J. Hoffman

Hoffman further noted that our study highlights the importance of stratifying or subgrouping autism risk genes to identify potential drug candidates using a precision medicine-based approach.

Why Zebrafish are Used as Model Organisms

Zebrafish, tiny tropical freshwater fish native to South Asia, have become essential in scientific research due to a genetic profile that is remarkably similar to that of humans. This similarity has previously allowed researchers to study various conditions, including melanoma and muscular dystrophy.

According to the Yale Zebrafish Research Core, these organisms offer several technical advantages for medical screening:

• They are optically transparent during much of their early development, which facilitates live imaging studies.
• They produce large numbers of offspring from a single crossing.
• Their larvae are fully active, behaving vertebrate organisms within days of fertilization.
• The larvae are small enough to fit into a 96-well plate format, making them ideal for chemical or genetic screens.
• The zebrafish genome is of high quality, and the transgenic tools used for the species are efficient and mature.

Research Methodology and Findings

The current research builds upon previous findings by Hoffman and her colleagues, who had identified how the disruption of 10 different autism risk genes in zebrafish affected basic sensory processing and sleep behaviors.

By combining this knowledge of risk genes with the 520-drug FDA database, the researchers were able to observe which medications could mitigate the behavioral disruptions caused by specific genetic mutations. This approach allows researchers to match specific drug candidates to specific genetic profiles rather than applying a universal treatment to a heterogeneous population.

The Yale Zebrafish Research Core continues to serve as a centralized repository for these services, providing the fish facility and experimental space necessary to model human diseases and facilitate small molecule screens for novel therapies.